573 related articles for article (PubMed ID: 8568620)
1. Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation.
Uchida T; Goto S; Foster TP
J Pharm Pharmacol; 1995 Jul; 47(7):556-60. PubMed ID: 8568620
[TBL] [Abstract][Full Text] [Related]
2. Oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation: particle size study.
Uchida T; Goto S
Biol Pharm Bull; 1994 Sep; 17(9):1272-6. PubMed ID: 7841952
[TBL] [Abstract][Full Text] [Related]
3. Dose and load studies for subcutaneous and oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin.
Uchida T; Martin S; Foster TP; Wardley RC; Grimm S
Pharm Res; 1994 Jul; 11(7):1009-15. PubMed ID: 7937541
[TBL] [Abstract][Full Text] [Related]
4. Effects of solvent selection and fabrication method on the characteristics of biodegradable poly(lactide-co-glycolide) microspheres containing ovalbumin.
Cho SW; Song SH; Choi YW
Arch Pharm Res; 2000 Aug; 23(4):385-90. PubMed ID: 10976588
[TBL] [Abstract][Full Text] [Related]
5. Microencapsulation of ovalbumin in poly(lactide-co-glycolide) by an oil-in-oil (o/o) solvent evaporation method.
Uchida T; Yagi A; Oda Y; Goto S
J Microencapsul; 1996; 13(5):509-18. PubMed ID: 8864988
[TBL] [Abstract][Full Text] [Related]
6. Controlled release microparticles for vaccine development.
O'Hagan DT; Jeffery H; Roberts MJ; McGee JP; Davis SS
Vaccine; 1991 Oct; 9(10):768-71. PubMed ID: 1759495
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of hCG-loaded polylactide or poly(lactide-co-glycolide) microspheres using a modified water-in-oil-in-water (w/o/w) emulsion solvent evaporation technique.
Zhu KJ; Jiang HL; Du XY; Wang J; Xu WX; Liu SF
J Microencapsul; 2001; 18(2):247-60. PubMed ID: 11253941
[TBL] [Abstract][Full Text] [Related]
8. Optimization of preparative conditions for polylactide (PLA) microspheres containing ovalbumin.
Uchida T; Yoshida K; Ninomiya A; Goto S
Chem Pharm Bull (Tokyo); 1995 Sep; 43(9):1569-73. PubMed ID: 7586084
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of a composite PLGA and poly(acryloyl hydroxyethyl starch) microsphere system for protein delivery.
Woo BH; Jiang G; Jo YW; DeLuca PP
Pharm Res; 2001 Nov; 18(11):1600-6. PubMed ID: 11758769
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres.
Shi L; Caulfield MJ; Chern RT; Wilson RA; Sanyal G; Volkin DB
J Pharm Sci; 2002 Apr; 91(4):1019-35. PubMed ID: 11948541
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.
Rosas JE; Hernández RM; Gascón AR; Igartua M; Guzman F; Patarroyo ME; Pedraz JL
Vaccine; 2001 Aug; 19(31):4445-51. PubMed ID: 11483270
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of poly-(D,L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres with entrapped pneumotropic bacterial antigens.
Kofler N; Ruedl C; Klima J; Recheis H; Böck G; Wick G; Wolf H
J Immunol Methods; 1996 Jun; 192(1-2):25-35. PubMed ID: 8699019
[TBL] [Abstract][Full Text] [Related]
13. Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis.
Duvvuri S; Janoria KG; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2007 Jun; 23(3):264-74. PubMed ID: 17593010
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable triblock copolymer microspheres based on thermosensitive sol-gel transition.
Kwon YM; Kim SW
Pharm Res; 2004 Feb; 21(2):339-43. PubMed ID: 15032317
[TBL] [Abstract][Full Text] [Related]
15. Preparation and in vitro/in vivo evaluation of insulin-loaded poly(acryloyl-hydroxyethyl starch)-PLGA composite microspheres.
Jiang G; Qiu W; DeLuca PP
Pharm Res; 2003 Mar; 20(3):452-9. PubMed ID: 12669968
[TBL] [Abstract][Full Text] [Related]
16. Instability of bovine insulin in poly(lactide-co-glycolide) (PLGA) microspheres.
Uchida T; Yagi A; Oda Y; Nakada Y; Goto S
Chem Pharm Bull (Tokyo); 1996 Jan; 44(1):235-6. PubMed ID: 8582042
[TBL] [Abstract][Full Text] [Related]
17. Self-encapsulating Poly(lactic-co-glycolic acid) (PLGA) Microspheres for Intranasal Vaccine Delivery.
Bailey BA; Desai KH; Ochyl LJ; Ciotti SM; Moon JJ; Schwendeman SP
Mol Pharm; 2017 Sep; 14(9):3228-3237. PubMed ID: 28726424
[TBL] [Abstract][Full Text] [Related]
18. Influence of formulation parameters on the characteristics of poly(D, L-lactide-co-glycolide) microspheres containing poly(L-lysine) complexed plasmid DNA.
Capan Y; Woo BH; Gebrekidan S; Ahmed S; DeLuca PP
J Control Release; 1999 Aug; 60(2-3):279-86. PubMed ID: 10425333
[TBL] [Abstract][Full Text] [Related]
19. Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit.
Horisawa E; Hirota T; Kawazoe S; Yamada J; Yamamoto H; Takeuchi H; Kawashima Y
Pharm Res; 2002 Apr; 19(4):403-10. PubMed ID: 12033371
[TBL] [Abstract][Full Text] [Related]
20. Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres.
Igartua M; Hernández RM; Esquisabel A; Gascón AR; Calvo MB; Pedraz JL
J Control Release; 1998 Dec; 56(1-3):63-73. PubMed ID: 9801430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
